Research · 2026-11-16
Clinical review examines kratom toxicity and gaps in pain-product evidence
Source: Orthopedic Reviews
Why it matters
A narrative review of nonprescription pain products examines kratom-related dependence, possible drug interactions and reports of organ toxicity. It also explains why variable formulations and other drug exposures limit conclusions about the risks of a particular product.
The big picture
The paper reviews existing literature rather than testing kratom in a new clinical trial. Its kratom section distinguishes traditional whole-leaf preparations from concentrated extracts and products enriched with 7-hydroxymitragynine. Reported reasons for using kratom, such as pain relief or opioid withdrawal, do not establish treatment effectiveness.
Key findings
- The authors describe a narrative PubMed review with additional targeted searches and reference screening. They imposed no strict publication-date limits and did not report a pooled estimate of kratom risk.
- The review links frequent use with dependence and withdrawal in existing studies. Physical dependence and withdrawal do not by themselves establish addiction in every user.
- Mitragynine can interact with drug-metabolizing enzymes, including CYP3A. The review identifies medication interactions as a clinical concern without establishing the risk for every drug combination or kratom preparation.
- Respiratory, seizure, cardiovascular and liver-injury reports are discussed. Many severe-event reports involve other substances or health conditions; they cannot establish that kratom alone caused every event or quantify population-level risk.
- Commercial alkaloid concentrations and possible contaminants vary. The authors call for standardized preparations, controlled clinical studies, quantitative exposure measurements and better evaluation of drug interactions.
What they say
The authors write that respiratory-event reports often involve polysubstance exposure, which makes it difficult to determine kratom’s independent contribution. They also caution that seizure reports do not establish a definitive dose-response relationship.
Bottom line
This review supports asking patients about kratom products and other medications, while leaving major uncertainties about product-specific toxicity and treatment benefit unresolved.